C21 · Pharmaceuticals · United States
Reference products with biosimilar approvals
United States: 8 in 2024.
- 8 Latest · United States · 2024
- Annual Release cadence
- 1 Record · 1 region · 2024
Verified 17 Sep 2026 · 1 publisher · Next period 2025
The figure
One published observation so far. A chart follows as soon as a second period is published.
Reference products with biosimilar approvals
United States, 2024
Every record
1 record · 1 region · 2024. Each period links to its record: the value, its source evidence and original document.
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: FDA. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (FDA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Number of originator biological reference products for which biosimilar therapies have been approved.
- Measure
- One slice of Reference products with biosimilar approvals ( form: count ) . Total number of originator biological reference products for which biosimilar therapies have received regulatory approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 | FDA | — | 1 |
Frequently asked questions
What is the latest reference products with biosimilar approvals?
United States: 8 in 2024.
Where does this data come from?
From 1 document published by FDA. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2024; the next release should cover 2025. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Reference products with biosimilar approvals [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/reference-products-with-biosimilar-approvals
"Reference products with biosimilar approvals." StatOrigin, 2026, https://statorigin.org/indicators/reference-products-with-biosimilar-approvals. Accessed 28 Oct. 2026.
StatOrigin. "Reference products with biosimilar approvals." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/reference-products-with-biosimilar-approvals.
@misc{statorigin_reference_products_with_biosimilar_approvals_2026, title = {Reference products with biosimilar approvals}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/reference-products-with-biosimilar-approvals}, note = {Data set. Accessed 2026-10-28} }